Libertini, Silvana (2008) Anaplastic thyroid carcinoma: novel therapeutic targets and strategies. [Tesi di dottorato] (Inedito)

[img]
Anteprima
PDF
Libertini_Oncologia_ed_Endocrinologia_Molecolare.pdf

Download (2MB) | Anteprima
Tipologia del documento: Tesi di dottorato
Lingua: English
Titolo: Anaplastic thyroid carcinoma: novel therapeutic targets and strategies
Autori:
AutoreEmail
Libertini, Silvana[non definito]
Data: 2008
Tipo di data: Pubblicazione
Numero di pagine: 101
Istituzione: Università degli Studi di Napoli Federico II
Dipartimento: Biologia e patologia cellullare e molecolare "L. Califano"
Dottorato: Oncologia ed endocrinologia molecolare
Ciclo di dottorato: 20
Coordinatore del Corso di dottorato:
nomeemail
Vecchio, Giancarlo[non definito]
Tutor:
nomeemail
Portella, Giuseppe[non definito]
Data: 2008
Numero di pagine: 101
Parole chiave: Anaplastic thyroid carcinoma
Settori scientifico-disciplinari del MIUR: Area 06 - Scienze mediche > MED/05 - Patologia clinica
Depositato il: 03 Lug 2008
Ultima modifica: 30 Apr 2014 19:31
URI: http://www.fedoa.unina.it/id/eprint/2630
DOI: 10.6092/UNINA/FEDOA/2630

Abstract

Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human malignancies, with a mean survival of only 6 months. Therefore, novel therapeutic approaches are desperately required. - dl1520 is a replication competent adenovirus that, due to lack of a functional E1B-55kD gene, can complete its life cycle solely in tumoural cells. We previously demonstrated that dl1520 efficiently kills ATC cells, but high multiplicity of infection (MOI) are required to obtain a significant antineoplastic effect. One of the major limiting factor in the efficient adenoviral transduction is the presence on cell surface of CAR receptor. Inhibition of the Raf/MEK/ERK pathway up-regulates CAR expression in cancer cells, thus improving adenoviral entry and cell killing by adenoviral mutants. To enhance its oncolytic activity, we decided to combine dl1520 with lovastatin, a drug that, blocking mevalonate synthesis, inhibits Raf/MEK/ERK pathway. However, lovastatin does not up-regulate CAR levels but, acting on viral genes expression, enhances viral replication. Indeed, lovastatin enhances in vitro and in vivo dl1520 effects, thus suggesting its potential role as dl1520 adjuvant in ATC therapy. - A common feature of anaplastic thyroid carcinoma is represented by aneuploidy. Aberrant expression of Aurora B occurs in solid tumours and it is associated with chromosome instability and carcinogenesis. Therefore, Aurora B expression has been evaluated in cell lines and samples from human thyroid carcinoma, showing that its expression paralleles the malignant phenotype. To establish a molecular target for ATC, Aurora B expression has been inhibited by RNAi or a specific inhibitor, showing that Aurora B inhibition blocks cell proliferation and cell survival.

Actions (login required)

Modifica documento Modifica documento